The terms of the IPO were not disclosed in the filing. Strong equity markets, falling interest rates and hopes of a ...

Weight-loss drug developer Metsera, backed by ARCH Venture Partners, filed its paperwork for an U.S. IPO on Friday. Strong ...

A new company is making its debut with a series A sum that’s sure to make hearts race. | A new company is making its debut ...

Metsera has filed for an initial public offering. The clinical-stage biopharmaceutical company submitted a registration statement to regulators on Friday, saying it intends to list under the ticker ...

The U.N. aviation agency on Friday said that 11,929 individuals had been affected by the unauthorized release of recruitment ...

“Jami is an industry-leading intellect and advisor to transformational healthcare companies,” said Mark Van Lith, CEO of Guggenheim Securities. “Jami is an important addition to our premier healthcare ...

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

Stanton Williams has been selected to design the Fleming Centre, a state-of-the-art research and public engagement facility ...

Kardigan, a heart health company modernizing cardiovascular drug development, launched today with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular ...

Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research ...

Discover why Arch Capital Group Ltd.'s recent share price weakness presents a buying opportunity with strong fundamentals.

The stock's fall snapped a two-day winning streak.